Accelrys Acquires Qumas - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelrys Acquires Qumas



Accelrys, a provider of scientific lifecycle management solutions, has acquired Ireland-based Qumas, a global provider of cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences, for $50 million.The Qumas acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document, and process management compliance solutions. Qumas’s quality management solutions supported by content and business process management capabilities will assist users to manage the scientific lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness, and increasing operational efficiency in bringing new products to market. Research, laboratory, and manufacturing informatics applications such as the Accelrys ELN (Electronic Lab Notebook), Accelrys LIMS (Laboratory Information Management System), Accelrys LES ( Lab Execution System) and Accelrys Discoverant for Operational Intelligence will function as data sources as well as integration points for the compliance and quality business systems managed by Qumas for CAPA, annual performance reports, and other submissions.

Source: Accelrys

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here